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Antipsychotic  drugs,  all of which  block  the  dopamine  D2  receptor  to a greater  or lesser  extent,  are  the
mainstay  for the  pharmacological  treatment  of schizophrenia.  Engaging  in a deeper  understanding  of
how antipsychotics  act  on the  brain  and  body,  at the  cellular,  molecular  and  physiological  level is  vital
to comprehend  both  the  beneﬁcial  and  potentially  harmful  actions  of  these  medications  and  stimulate
development  of  novel  therapeutics.  To  address  this,  we review  recent  advances  in  our  understanding
of  neuroadaptations  to  antipsychotics,  focusing  on  (1)  treatment  efﬁcacy,  (2)  impact  on  brain  volume
and  (3)  evidence  from  human  post-mortem  studies  that  attempt  to dissect  neuropathological  effects  of
antipsychotic  drugs  from  organic  schizophrenia  neurobiology  and  (4)  cardio-metabolic  side  effects.  Our
aim  is  to stimulate  discussion  on  these  highly  clinically  relevant  topics  and  consider  how  we  might  use
current  and  evolving  knowledge  and  new  methodologies  in  the  ﬁelds  of neuropharmacology  and  neuro-onoamine
euroadaptation
nsulin
reatment efﬁcacy/failure
science,  to advance  our  understanding  of the  long-term  impact  of antipsychotic  treatment.  Ultimately,
this  may  inform  the  clinical  use  of  these  drugs.
©  2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).ost-mortem
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Schizophrenia is a debilitating disease, ranked among the top 20
auses of disability worldwide (van Os and Kapur, 2009). The pre-
ise burden to society is difﬁcult to estimate with precision, due
o the diversity of data available and the manner in which it has
een collected, nevertheless, large-scale studies examining indica-
ors of the cost-of-illness generally suggest a disquieting picture of
ubstantial human and economic costs. The lifetime prevalence of
chizophrenia has been estimated at 0.25% in North America and
.52% in Europe (Simeone et al., 2015). Indeed, in the European
nion alone, a 2011 estimate suggested up to 5 million citizens
uffer from schizophrenia and related psychoses (Wittchen et al.,
011). Schizophrenia is not purely a disease of mental health;
atients have higher mortality rates and die 12–15 years (on aver-
ge) earlier than the general population (Saha et al., 2007). It may
urprise some then, that schizophrenia leads to more loss of life
han several cancers and other physical illnesses (van Os and Kapur,
009). Whilst many of these deaths reﬂect suicide, the primary
eason for increased mortality is physical causes, including cardio-
ascular disease (Hennekens et al., 2005; Saha et al., 2007).
After diagnosis of schizophrenia, for which there is still no objec-
ive diagnostic test (Fond et al., 2015; Prata et al., 2014), the clinical
anagement of this devastating disorder is very much grounded in
he use of antipsychotic drugs (APD) (Kapur and Mamo,  2003), all
f which act at dopamine D2 receptors. Unfortunately, these drugs
o not effectively treat all symptom dimensions, particularly nega-
ive and cognitive symptoms. Furthermore they are associated with
umerous side effects, decrease in efﬁcacy over time, and a sub-
tantial proportion of patients fail to respond to multiple courses
f APD, leaving a signiﬁcant unmet medical need (Kapur and Mamo,
003). Now more than 50 years since the introduction of these med-
cations, little real progress has been made in advancing towards
ovel, non-dopaminergic therapeutics, despite decades of research
ffort and spending (Millan et al., 2015). In part, this reﬂects our
merging understanding of the complex, multi-factorial nature of
chizophrenia pathophysiology, driven by advances in psychiatric
enetics (Anon, 2014, 2015; Fromer et al., 2014), post-mortem brain
issue studies, and neuroimaging, particularly in prodromal indi-
iduals who have yet to transition to psychosis (Bloomﬁeld et al.,
015; Crossley et al., 2015; Demjaha et al., 2014; Howes et al., 2015;
ambeitz et al., 2014; Selvaraj et al., 2014; van Erp et al., 2015).
ombined, these approaches are beginning to paint a picture that
chizophrenia is a complex syndrome, with likely multiple aetiolo-
ies and potentially distinct neurobiological phenotypes that may
ave profound implications for clinical treatment strategies. These
nsights will undoubtedly, in the fullness of time, provide the key
ieces of information that will unlock novel drug treatments for
chizophrenia, beyond dopamine and the D2 receptor.
On the other hand, such success is unlikely to be immediate.
iven the medical need, there is another view, which suggests
hat engaging in a deeper understanding of how currently used
PD act on the brain and the body, by dissecting their cellular,
olecular and physiological effects in relevant model systems, is of
aramount importance to speed the quest for new and improved
edications. Such a systematic approach is likely to yield cru-
ial insights into the mechanisms underlying the beneﬁcial and
otentially harmful effects of these drugs. This can provide logical
outes to adjunct treatments, some of which, particularly anti-
nﬂammatory drugs, are already showing encouraging signs of
uccess in the clinic (Sommer et al., 2014). Furthermore, if one can
etter understand the cellular, molecular and physiological basis ofPlease cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
he positive and negative effects of APDs, there is the potential to
se rational drug design to develop novel antipsychotic agents that
etain the beneﬁcial effects, without the adverse ones (Cohen et al.,
013). In this review, we address this issue, by combining informa- PRESS
avioral Reviews xxx (2016) xxx–xxx
tion from different, but parallel, research lines, with a common goal
− to understand at the cellular and molecular level, the effects of
long-term APD treatment on the brain and body, which ultimately,
may  inform the clinical use of these drugs and the development
of new APD. In doing so, we ﬁrst brieﬂy introduce the history
of the development and current application of modern antipsy-
chotics. We  then present evidence from parallel lines of research
into APD, focussing in particular on three key areas: (1) treat-
ment efﬁcacy and failure, (2) potential impact on brain structure
and (3) metabolic side effects. We  also review the evidence from
human post-mortem studies to dissect neuropathological effects of
antipsychotics from schizophrenia neurobiology. Our overall aim is
to stimulate a critical discussion on these highly clinically relevant
topics. In particular, we aim to inspire debate on how we  might
use current and evolving knowledge and new methodologies in
the ﬁelds of neuropharmacology and neuroscience to advance our
understanding of the long-term impact of APD treatment, which
ultimately, may  inform the clinical use of these drugs.
1.1. Clinical use of antipsychotic drugs for the treatment of
schizophrenia: concerns and controversies
Antipsychotics remain the mainstay of pharmacological treat-
ment of schizophrenia (Kapur and Mamo,  2003; Samara et al.,
2014). These drugs are classiﬁed into First Generation Antipsy-
chotics (FGA), also referred to as typical antipsychotics, of which
haloperidol and chlorpromazine are the prototypical examples, and
the newer Second Generation Antipsychotics (SGA), or atypical
antipsychotics, examples of which include risperidone, olanzap-
ine, quetiapine, ziprasidone, and most recently aripiprazole and
brexpiprazole (sometimes referred to as Third Generation Antipsy-
chotics). FGAs were discovered serendipitously in the 1950′s and
remain effective in the treatment of psychotic symptoms. How-
ever, based on initial optimism that SGA are more effective in
improving negative and cognitive symptoms of schizophrenia, as
well as their more favourable side effect proﬁles, these agents have
largely supplanted the use of FGA in clinical practice and treatment
guidelines. Without question, SGA are effective in treating posi-
tive symptoms and are associated with signiﬁcantly less motor side
effects. However, the initial promise of efﬁcacy in other domains
remains controversial (Leucht et al., 2013).
The use of APD has dramatically increased over the past decade
and more than 50 million prescriptions are dispensed annually
(Snyder and Murphy, 2008). Importantly, in addition to psychosis,
antipsychotics are increasingly being prescribed for use, under
certain circumstances, in the treatment of depression, bipolar dis-
order and behavioural sedation in autism spectrum disorder (ASD)
(Domino and Swartz, 2008; Kaye et al., 2003). In addition, there
is increasing “off-label” prescription for anxiety disorders, insom-
nia and behavioural sedation in dementia patients (Maher et al.,
2011). This increasing use, particularly of SGA, assumes that these
drugs have few long-term adverse effects or other clinical issues.
However, it has long been known that FGA are associated with a
higher prevalence of extra-pyramidal symptoms (EPS), including
tardive dyskinesia and akathasia, resulting in cautious use clini-
cally (Lerner et al., 2015). Whilst the newer SGA have a much lower
EPS liability (Rummel-Kluge et al., 2012), they come with different
risks and challenges for patients and physicians alike. In particu-
lar, these drugs are associated with a high incidence of metabolic
side effects including weight gain, metabolic syndrome and ele-
vated risk for type-II diabetes (Mitchell et al., 2013a,b). Moreover,
in recent years increasing evidence has emerged from both clinicals to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
studies and basic research to suggest a link between the dose and
duration of APD treatment and a progressive loss of grey matter,
which if true, may  have signiﬁcant clinical implications (Vita et al.,
2015). Aside from the adverse effects of these medications, another
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revailing issue of fundamental importance is that the therapeu-
ic response to APD is not only mixed, but also may  decline with
ime (Kane et al., 2013; Kishimoto et al., 2013; Leucht et al., 2013).
 substantial proportion of schizophrenia patients (up to 40%) also
o not respond to ﬁrst-line standard APD treatment. These individ-
als, described as “treatment resistant” represent a signiﬁcant area
f unmet medical need (Remington et al., 2014). Taken together, it
s clear that whilst APD remain the mainstay for pharmacological
ntervention in schizophrenia, their use is not without risk, suggest-
ng a cost: beneﬁt proﬁle that requires careful clinical management.
oreover, the mechanisms underlying these phenomena and the
linical implications remain poorly understood.
Advances in neuropsychopharmacology, neuroscience and neu-
oimaging techniques have allowed us to probe deeper into the
ction of APD at the molecular, neuropsychological and systems
evel to reveal how the brain and peripheral systems adapt to
PD treatment. In the following sections we synthesise from this
vidence base, to which we have contributed as authors, the cur-
ent state-of-the art regarding the effects of APD on brain and
ody systems relevant both to the beneﬁcial and potentially harm-
ul aspects of these medications. Speciﬁcally, we  ﬁrst consider
euroadapatations relevant to treatment efﬁcacy, particularly con-
idering the dogma that all antipsychotics have similar efﬁcacy.
ere we present for the ﬁrst time a new correlative analysis to
hallenge this notion. Second, we consider the growing evidence
or effects of antipsychotics on brain structure and function from
oth clinical and preclinical studies, and the possible implications
f this effect. Motivated by a seminal review of the neuropatho-
ogical effects of APD (Harrison, 1999a), we update the available
vidence from human post-mortem studies as to what constitutes
isease-speciﬁc effects and what may  potentially represent med-
cation confounds, a fundamental challenge in unravelling the
eurobiology of schizophrenia. Finally, we turn to the long-known
elationships between antipsychotics and metabolic disturbances,
ith a speciﬁc focus on insulin signalling.
.2. Classiﬁcations of antipsychotic drugs and their clinical
fﬁcacy
The question of which antipsychotic drugs (APD) should be
referred for treatment of schizophrenia is controversial, largely
ecause of the substantial costs of SGAs (Leucht et al., 2013). Meta-
nalytical evidence of clinical trial data regarding efﬁcacy suggests
hat clozapine is signiﬁcantly more effective than all other SGAs
Leucht et al., 2013). After which, amisulpride, olanzapine, and
isperidone are signiﬁcantly more effective than the other drugs
part from paliperidone and zotepine, although these effect sizes
ere small (Cohen’s d; range 0·11–0·33) (Leucht et al., 2013). These
ata challenge the dogma that the efﬁcacy of atypical APD is the
ame. Dominant and unifying theories along with experimental
nd clinical evidence suggests that the efﬁcacy of APD (except for
ripiprazole) strictly depends on blocking dopamine D2 receptors
Creese et al., 1976; Kapur et al., 2000; Seeman et al., 1976).
Yet, the binding afﬁnity proﬁle of APD is substantially different.
ntipsychotics bind virtually all neurotransmitter receptors, to a
reater or lesser extent (Lieberman et al., 2008). Traditionally, FGA
re seen as having higher binding afﬁnity towards D2 receptors
ompared to SGA, which instead show low afﬁnity for D2 receptors
Creese et al., 1976; Kornhuber et al., 1989; Seeman et al., 1976).
thers have alternatively argued, based on multivariate statisti-
al analysis, that the main mechanistic difference between FGA
nd SGA is the relative binding afﬁnity towards 5-HT2A and D2Please cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
eceptors (Meltzer et al., 1989). In fact, Meltzer et al. have shown
hat SGA, but not FGA, displayed higher binding afﬁnity for 5-HT2A
han for D2 receptors, a pharmacological marker that is notably
ummarized as a 5-HT2A/D2 ratio. Although the 5-HT2A/D2 ratio PRESS
vioral Reviews xxx (2016) xxx–xxx 3
has been constructively criticized as to whether it is a clinically-
relevant mechanism (Kapur and Seeman, 2001), the theory based
on the 5HT2A/D2 ratio is still considered central to discriminate
FGA from SGA (Meltzer et al., 1989) and it is widely used to interpret
a priori clinical outcomes of APD.
In the literature however there is little evidence of whether
the 5-HT2A/D2 ratio contributes to clinical outcomes, such as efﬁ-
cacy and/or side effects, for the newer SGA, in light of the latest
meta-analytic data. A recent multiple-treatments meta-analysis
has shown signiﬁcant differences in several therapeutic parame-
ters even within same drug categories (Leucht et al., 2013). This
novel evidence thus sets up a number of new questions. For exam-
ple, from a drug development stand point, what is the relationship
between the 5-HT2A/D2 ratio and clinical outcomes? Furthermore,
is the 5-HT2A/D2 ratio suitable to discriminate FGA from SGA? In an
attempt to answer these questions, here we review the literature
using a correlative analysis to unravel the potential relationships
between the serotoninergic mechanisms of APD, clinical outcomes
and classiﬁcations.
Speciﬁcally, we have carried out a correlative analysis between
5-HT2A/D2 ratio of SGA and FGA and their overall efﬁcacy along
with all-cause discontinuation as reported by (Leucht et al., 2013).
According to the terminology used by Leucht et al. (Leucht et al.,
2013), here we refer to overall efﬁcacy as the mean overall change
in symptoms (positive and negative – total score from baseline to
endpoint – as detected by standard tests, see (Leucht et al., 2013).
All-cause discontinuation instead refers to any factors that have
led to treatment discontinuation (Leucht et al., 2013). This includes
weight gain, the use of anti-parkinsonian medication as an index
of extrapyramidal side effects, increases in prolactin levels, the
presence of electrocardiographic abnormalities and sedative effects
(Leucht et al., 2013). Our correlative analysis has also explored
the relationship between 5-HT2A/D2 ratio and extrapyramidal
side effects separately from all-cause discontinuation. Addition-
ally, the association between clinical effects and ability to stimulate
cortical and subcortical serotonin release, as measured with micro-
dialysis in pre-clinical models was  examined. A recent review
has already suggested the relevance of analysing antipsychotic-
driven neurochemical output patterns (e.g. the serotonin pattern
− deﬁned as changes in the extracellular levels of serotonin), in
pre-clinical models, to possibly predict clinical outcomes (Amato,
2015). In fact, it has been hypothesised that the symptoms of
schizophrenia reﬂect unbalanced monoaminergic activity in corti-
cal and subcortical areas (Carlsson et al., 1997), with antipsychotics
improving symptoms by correcting this imbalance. It has also been
speculated whether changes in serotonin release, as observed in
animal models, could alone predict the clinical outcomes of SGAs.
These additional mechanistic effects of APD are often underesti-
mated. However, the powerful idea to study the neurochemical
patterns of APD lies also in the perspective to investigate more
complex mechanisms than mere receptor binding activity. In fact,
it should be acknowledged that the neurochemical output driven
by antipsychotics is not simply related to blocking receptors, given
that neurotransmission depends on multiple complex mechanisms
involving the complete synthesis, release and uptake machinery.
The following correlative analysis is focused on APD that were
recently studied in a multiple-treatment meta-analysis compar-
ing the efﬁcacy and tolerability of SGAs plus chlorpromazine and
haloperidol (Leucht et al., 2013). To make our analysis possible
we used arithmetic means of receptor binding constants, obtained
from at least two independent studies using both humans and
animals. The necessity of using averaged receptor binding con-s to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
stant values is dictated by the heterogeneous ﬁgures attained by
each of those studies. The serotonin neurotransmission pattern was
obtained from pre-clinical studies, following acute APD treatment
using microdialysis, as described in (Amato, 2015).
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Table 1
Comparative correlations of antipsychotic drugs 5-HT2A/D2 Ki ratio and clinical outcomes.
Clinical outcome ranks*
Antipsychotic drugs 5-HT levels a (%baseline) 5-HT2A b D2 b 5-HT2A/D2 Ki rank b Overall efﬁcacy Side-effects All-cause discontinuation
Olanzapine 72.86 2.8 28 0.1 3 1.0 0.46
Clozapine 61 5 16.67 0.3 1 0.3 0.46
Risperidone 172 0.2 0.5 0.4 4 2.09 0.53
Zotepine 127.5 9.8 19.6 0.5 6 3.01 0.69
Quetiapine 136 189.3 315.5 0.6 8 1.01 0.61
Asenapine 97.41 c 5.5 6.9 0.8 13 1.66 0.69
Lurasidone 82.17 2 1.7 1.2 14 2.46 0.77
Chlorpromazine 48 6.7 4.19 1.6 12 2.65 0.65
Aripiprazole 67.37 8.7 0.55 15.8 9 1.20 0.61
Haloperidol 49.71 52.4 1.64 31.9 7 4.76 0.8
Receptor binding constants (nM) are mean values from humans and rats [b Refs. (Ichikawa et al., 2002; Ishibashi et al., 2010; Kroeze et al., 2003; Meltzer et al., 1989; Needham
et  al., 1996; Richelson and Souder, 2000; Richtand et al., 2007; Shahid et al., 2009; Werner et al., 2013)]. The 5-HT levels (%baseline) are mean values from rodents [aRef.
(Amato, 2015) and c Refs. (Bjorkholm et al., 2015; Franberg et al., 2009; Franberg et al., 2012)]. * Ref. (Leucht et al., 2013).
Table 2
Comparative correlations of antipsychotic drugs 5-HT2A brain levels and clinical outcomes.
Clinical outcome ranks*
Antipsychotic drugs 5-HT2A/D2 b 5-HT2A b D2 b 5-HT levels rank a (%baseline) Overall efﬁcacy Side-effects All-cause discontinuation
Risperidone 0.4 0.2 0.5 172.00 4 2.09 0.53
Quetiapine 0.6 189.3 315.5 136.00 8 1.01 0.61
Zotepine 0.5 9.8 19.6 127.50 6 3.01 0.69
Asenapine 0.8 5.5 6.9 97.41 c 13 1.66 0.69
Lurasidone 1.2 2 1.7 82.17 14 2.46 0.77
Olanzapine 0.1 2.8 28 72.86 3 1.0 0.46
Aripiprazole 15.8 8.7 0.55 67.37 9 1.20 0.61
Clozapine 0.3 5 16.67 61.00 1 0.3 0.46
Haloperidol 31.9 52.4 1.64 49.71 7 4.76 0.8
Chlorpormazine 1.6 6.7 4.19 48.00 12 2.65 0.65
The 5-HT levels (%baseline) are mean values from rodents [aRef. (Amato, 2015) and c Refs. (Bjorkholm et al., 2015; Franberg et al., 2009; Franberg et al., 2012)]. Receptor
binding  constants (nM) are mean values from humans and rats [b Refs. (Ichikawa et al., 2002; Ishibashi et al., 2010; Kroeze et al., 2003; Meltzer et al., 1989; Needham et al.,
1996;  Richelson and Souder, 2000; Richtand et al., 2007; Shahid et al., 2009; Werner et al., 2013)]. * Ref. (Leucht et al., 2013).
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Our correlative analysis could only include 10 of the 15 antipsy-
hotics examined by (Leucht et al., 2013), due to the lack of
icrodialysis studies investigating the serotonin neurotransmis-
ion proﬁle of amisulpride, paliperidone, sertindole, ziprasidone
nd iloperidone (Amato, 2015). The general data used in the cor-
elative analysis are reported in Tables 1 and 2. Regarding the use
f the serotonin 5-HT2A/D2 ratio as a predictive factor for clinical
utcomes, we found that this measure was signiﬁcantly associated
ith the overall efﬁcacy of most APD (p < 0.05), with the exceptionsPlease cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
f aripiprazole and haloperidol (Fig. 1A, B). Since the latter antipsy-
hotics skewed the representation of the data in all domains to the
eft, aripiprazole and haloperidol are plotted on an independent x-
xis (Figs.1B, 2B C). Furthermore, the 5-HT2A/D2 ratio signiﬁcantlyA and FGA drugs and their 5-HT2A/D2 ratio.
predicted all-cause discontinuation (p < 0.05, Fig. 2D), but not extra-
pyramidal side effects (p > 0.05, Fig. 2A). Regarding the use of the
serotonin levels (% of baseline) as a predictive factor for clinical
outcomes, we found that serotonin levels were signiﬁcantly asso-
ciated with the overall efﬁcacy of risperidone, quetiapine, zotepine,
asenapine and lurasidone (p < 0.01, Fig. 3), but not with the over-
all efﬁcacy of clozapine, olanzapine, haloperidol, aripiprazole and
chlorpromazine (p > 0.05, Fig. 3 – empty dots). To highlight the
marked relationship patterns among antipsychotics, they are plot-s to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
ted in the same axes (Fig. 3). Finally, serotonin levels signiﬁcantly
predicted all-cause discontinuation during risperidone, quetiap-
ine, zotepine, asenapine or lurasidone treatment (p < 0.01, Fig. 4D)
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ffects on extracellular 5-HT changes in the naïve rodent brain.
ut not during clozapine, olanzapine, haloperidol, aripiprazole or
hlorpromazine treatments (p > 0.05, Fig. 4C).
The results of this analysis therefore suggest that both the 5-
T2A/D2 ratio and the serotonin output are predictors of APD
verall efﬁcacy and of all-cause discontinuation (Figs.1A, 2D, 3).
 low 5-HT2A/D2 ratio was associated with the highest efﬁcacyPlease cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
nd with lowest discontinuation, while high serotonin levels were
ssociated with highest efﬁcacy and with the lowest discontinu-
tion (see ranks in Table 2), although only within a sub-group of
ntipsychotics. The latter may  suggest that the main action mech-(C, D) observed during SGA and FGA drug treatment and their 5-HT2A/D2 ratio.
anism of subgroup of antipsychotics is expressed by stimulating
serotonin release, which better links with their clinical outcome. It
was previously observed that SGA and FGA have a different sero-
toninergic binding and activity proﬁle (Amato, 2015) that may be
the underlying mechanism of the results of the present correlations.
Perhaps a low afﬁnity antagonism for 5-HT1A receptor associated
with a high afﬁnity antagonism/inverse agonism may  be key for the
role of serotonin pattern in clinical outcomes. Other compounds
like clozapine, instead, show a high afﬁnity partial agonism for
5-HT1A receptors and a high afﬁnity antagonism for 5-HT2A recep-
tor, which may  maintain a low release of serotonin but promote
dopamine release (Amato, 2015).
At ﬁrst glance, it appears that the 5-HT2A/D2 ratio is therefore a
better predictor of antipsychotic efﬁcacy than the serotonin out-
put criterion, as the latter was only able to predict the efﬁcacy
of a smaller number of compounds with a medium-to-low efﬁ-
cacy rank coefﬁcient. Alternatively, the higher predictive power
of the 5-HT2A/D2 ratio may  also be seen as a consequence of its
lower discrimination properties. In fact, all antipsychotics, except
for haloperidol, aripiprazole and chlorpromazine displayed a low
5-HT2A/D2 coefﬁcient; therefore the predictive power of the 5-
HT2A/D2 ratio may  reﬂect this greater number of compounds
rather than selectivity per se.  If this were the case, the ratio coefﬁ-
cient may  not be suitable as either a mechanistic criterion to predict
clinical outcomes, or as a criterion to classify antipsychotics as FGA
or SGA.
The serotonin output pattern, while predicting the efﬁcacy ofs to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
only some antipsychotics may  provide more accurate information
on the relevance of neurochemical mechanisms. For example, it
suggests that some antipsychotics are serotoninergic and others
ARTICLE IN PRESSG ModelNBR-2622; No. of Pages 19
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re not. In practice, the term “serotonin indirectly releasing agents”
s more appropriate since these compounds facilitate the release
f serotonin via agonism and antagonism of autoreceptors and/or
ostsynaptic receptors. Also, antipsychotics can affect the release
f serotonin via other neurotransmitter systems summarized in
Amato, 2015).
Particularly, according to the present analysis, the newer SGAs,
ut not the traditional SGAs or FGAs, may  be classiﬁed as sero-
onin releasing agents. While serotonin-releasing antipsychotics
esulted in the present analysis to be overall less effective than
he non- serotonin releasing agents, they are however associated
ith the lowest treatment discontinuation. Therefore, although the
-HT2A/D2 ratio is a better predictor of efﬁcacy than the sero-
onin output pattern, it appears to be a less selective classiﬁcatory
riterion and poorly discriminates downstream effects of antipsy-
hotics. Instead, the serotonin output pattern may  provide a better
lassiﬁcatory criterion to deﬁne clinical outcomes for newer SGAs.
These new observations may  be of relevance in disentan-
ling and surpassing the commonly-held view of SGA and FGA
echanisms of action, which are currently based on receptor bind-
ng afﬁnity. The systematic association of the clincial effects of
ntipsychotics with their neurotransmitter output patterns has the
otential to generate a classiﬁcation paradigm based on a neu-
otransmission domain (see Fig. 5 as an example). As such, the
lassiﬁcation of antipsychotics as either serotonin or dopamine (orPlease cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
lutamate and so on) indirectly releasing agents may  be a better
redictor of clinical outcomes and treatment reponse. A limitation
f the present analysis however is that we used the 5-HT levelFig. 5. A proposal for classifying antipsychotic drugs based on their modulation of
a  speciﬁc neurotransmitter domain in relation to different symptom clusters.
output following a single dose of antipsychotic, to compare with
their clinical effects achieved using repeated and multiple doses
of the same drugs. However, it should be noted that patients with
schizohrenia often receive escalating doses of antipsychotic over
their life time, thus partially mimicking the acute effects of the
initial treatment. Further studies in pre-clinical models to assesss to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
the impact of chronic APD treatment on neurotransmitter levels,
particularly serotonin, will help to clarify this.
To the best of our knowledge this is the ﬁrst review analyzing
the relationships between conventional APD mechanistic dogma
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nd clinical outcomes, as measured with multiple treatment meta-
nalysis. Furthermore, this is the ﬁrst time that clinical outcomes
re considered in relation to the serotonin output driven by APD,
lthough the idea to relate antipsychotic efﬁcacy with their effects
n neurochemical release was previously advanced (Westerink,
002).
.3. Neuroadaptations to antipsychotic drugs
.3.1. Impact of chronic antipsychotic drug treatment on brain
orphology: a cause for concern?
Post-mortem and in vivo magnetic resonance imaging (MRI)
tudies have over the last four decades, contributed substantially
o our understanding of the neurobiology and pathophysiology
f schizophrenia. Post-mortem brains from schizophrenia patients
how signiﬁcant structural abnormalities (Andreasen et al., 1982a,
982b, 1982c; Crow et al., 1989; Harrison, 1999b; Johnstone et al.,
976; Narr et al., 2005; Zipursky et al., 1998) with evidence for
light shrinkage (∼5%) of the brain in terms of weight, length,
nd cortical volume (Gur et al., 1998a, 1998b; Johnstone et al.,
976) and for enlarged (∼15%) ventricles (Cahn et al., 2002a;
ahn et al., 2002b; Crow et al., 1989; DeLisi et al., 1995; Gur
t al., 1998a, 1998b; Johnstone et al., 1976; Lieberman et al.,
001). Advances in MRI  acquisition and computational anatomy
pproaches have also revealed the presence of structural brain
bnormalities in schizophrenia patients. Reductions in the volume
f the whole-brain, temporal and frontal lobe grey matter vol-
me  and enlargement of the lateral ventricles are among the most
eplicated ﬁndings based on meta-analytical evidence (Ellison-
right et al., 2008; Glahn et al., 2008; Haijma et al., 2013; Wright
t al., 2000). Recently, the ENIGMA consortium reported the largest
rospective meta-analysis of neuroimaging data from schizophre-
ia patients (n = 2028) and controls (n = 2540) to date (van Erp
t al., 2015). Using data from 15 different centres worldwide, the
uthors report evidence for reductions in the grey matter volume
f the hippocampus (Cohen’s d = −0.46), amygdala (d = −0.31), tha-
amus (d = −0.31), accumbens (d = −0.25) and intracranial volumes
d = −0.12), as well as larger pallidum (d = +0.21) and lateral ventri-
le volumes (d = +0.37) (van Erp et al., 2015).
These neuroanatomical abnormalities appear to be evident from
he ﬁrst episode of schizophrenia (Vita et al., 2006) and are sug-
ested to be detectable before illness onset in prodromal/high-risk
ndividuals (Cannon et al., 2015; Dazzan et al., 2012; Mechelli et al.,
011; Pantelis et al., 2003; Schobel et al., 2013), although the data
re not completely equivocal in this respect (Haukvik et al., 2015;
oiz-Santianez et al., 2015; van Haren et al., 2007). Meta-analyses
f longitudinal MRI  studies, which have the advantage of com-
aring back to baseline states, provide evidence to suggest that
hese brain volume abnormalities in schizophrenia may  be progres-
ive, with whole-brain and cortical grey matter volumes decreasing
nd lateral ventricle volumes increasing over time both in ﬁrst-
pisode and chronic schizophrenia patients (Fusar-Poli et al., 2013;
empton et al., 2010; Olabi et al., 2011; Vita et al., 2012).
Nevertheless, important questions remaining concerning neu-
oanatomical changes in schizophrenia, as detected by MRI. The
rst concerns the potential contribution of APD to the above men-
ioned brain volume abnormalities. The second relates to whether
hese anatomical changes are progressive with time. Both top-
cs are the subject of lively and intense debate (Van Haren et al.,
013; Zipursky et al., 2013). Importantly, the presence of brain
tructural and functional abnormalities prior to any medication
xposure, as highlighted by data from studies mentioned above,Please cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
learly suggests that APD are not the sole cause of brain volume
hanges in schizophrenia patients. Nevertheless, in the last two
ecades, increasing evidence has come to light to support the fact
hat APD exposure may  well contribute to some of the neuroanatom- PRESS
vioral Reviews xxx (2016) xxx–xxx 7
ical abnormalities in schizophrenia patients. While the data are
not unequivocal (Lewis, 2009; Weinberger and McClure, 2002), the
increasing use of antipsychotics, particularly off-label prescribing,
makes it critical that this issue is examined rigorously.
The largest meta-analysis of cross-sectional MR  imaging stud-
ies on schizophrenia performed to date with data from over
∼18,000 subjects (Haijma et al., 2013) indicates that reductions in
whole-brain grey matter volume are associated with the dose of
antipsychotics taken at the time of scanning. Data from longitudi-
nal MRI  investigations however, have the potential to provide the
most compelling evidence for these potential medication effects,
particularly if the assessment is carried out after the ﬁrst episode
of psychosis (FEP) and captures subsequent exposure to APD. Syn-
thesising the evidence from such studies suggests that long-term
exposure to APD is associated with sub-cortical grey matter volume
enlargement, particularly in the caudate-putamen and pallidum
and the loss of cortical grey matter volume (Cahn et al., 2002b; Gur
et al., 1998a; Lieberman et al., 2005b; Thompson et al., 2009; Wood
et al., 2001) and thickness (van Haren et al., 2011), supported by
three systematic reviews on the subject (Moncrieff and Leo, 2010;
Navari and Dazzan, 2009; Smieskova et al., 2009). The largest lon-
gitudinal study to date investigated the trajectory of brain volume
changes in FEP patients (n = 211) soon after illness onset, yielding
a total of 674 high-resolution magnetic resonance scans. On aver-
age, each patient had 3 scans (≥2 and as many as 5) over 7.2 years
(up to 14 years) (Ho et al., 2011). Data from this study and a follow
up investigation of the same sample (Andreasen et al., 2013) con-
ﬁrmed that decreases in whole brain and regional grey and white
matter volumes were signiﬁcantly associated with higher exposure
to APD. Notably, these ﬁndings remained signiﬁcant after control-
ling for illness duration, illness severity, and substance abuse (Ho
et al., 2011).
These ﬁndings are supported by recent meta-analysis of data
from longitudinal MRI  studies, which suggests a signiﬁcant cor-
relation between cumulative APD intake during the inter-scan
interval and decreases in whole brain grey matter (Fusar-Poli
et al., 2013). Similarly, activation likelihood estimation meta-
analysis of voxel-based anatomical MRI  data suggests brain regions
that may  be speciﬁcally affected following antipsychotic treat-
ment in schizophrenia patients. These include relative volumetric
decreases in the anterior cingulate and insular cortices (Radua et al.,
2012), left lateral temporal cortex, left inferior frontal gyrus, supe-
rior frontal gyrus and right rectal gyrus (Torres et al., 2013). In
contrast with prior results (Radua et al., 2012), areas of relative
volumetric increase have also been identiﬁed in the left dorsal
anterior cingulate cortex, left ventral anterior cingulate cortex and
right putamen (Torres et al., 2013). More recently, other longitudi-
nal studies, particularly those from the North Finland Birth Cohort
study (1966 sample), have provided additional evidence to suggest
that the dose and duration of APD treatment may  predict grey mat-
ter volume loss in schizophrenia patients (Guo  et al., 2015; Veijola
et al., 2014). On the other hand, it is important to note that there
are longitudinal studies that have reported no association between
cumulative antipsychotic exposure and progressive brain volume
alterations in schizophrenia patients although in some cases, the
sample sizes are typically small and the duration of follow up is
variable across studies (DeLisi et al., 1995; Haukvik et al., 2015;
Kubota et al., 2015; McClure et al., 2008; Roiz-Santianez et al., 2015;
Velakoulis et al., 2006).
Despite the weight of available neuroimaging evidence strongly
suggesting an effect of APD on brain volume, the lack of longitudi-
nally followed untreated patients as a control means it remainss to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
unclear whether this outcome is the effect of illness progression
or drug treatment. Furthermore, as MRI  currently cannot visualise
changes at the cellular level, none of the human studies are able
to link the imaging changes to post-mortem ﬁndings and therefore
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he relationship between imaging-related structural changes and
ost-mortem ﬁndings remains unclear (Harrison, 1999a,b). More-
ver, an enduring debate remains concerning the potential for a
ifferential impact of FGA and SGA on progressive loss of grey
r white matter (Vita et al., 2015). For example, hypertrophy of
he caudate-putamen has long been thought to predominate in
atients treated principally with FGA. However, a recent systematic
eview and new evidence in which clozapine-treated subjects are
xcluded from the SGA group questions this assumption (Ebdrup
t al., 2013; Jorgensen et al., 2015). Reports of altered hippocam-
al volume following APD treatment are also inconsistent. Data
rom the ENIGMA schizophrenia-working group in fact suggests
hat the degree of hippocampus volume shrinkage is greater in
edication naïve schizophrenia patients as compared to medicated
atients, most of which were receiving SGA (van Erp et al., 2015).
n contrast, longitudinal studies of cortical grey matter volume and
hickness in schizophrenia patients have consistently identifed, dif-
erent trajectories of volume or cortical thickness changes in those
atients receiving SGA as compared to FGA (Ansell et al., 2015;
ieberman et al., 2005b; Thompson et al., 2009; van Haren et al.,
008; van Haren et al., 2007, 2011). In the Iowa Longitudinal study,
atients were treated naturalistically, thus there were no direct
omparisons of the different APD classes (Ho et al., 2011). A recent
eta-analysis has added to this debate (Vita et al., 2015). Here,
he authors reported the results of a subgroup meta-analyses of
tudies on schizophrenia patients treated with either FGA or SGA.
his revealed a differential and contrasting moderating role of APD
ntake on cortical grey matter changes, with more progressive grey
atter loss correlating with higher mean daily antipsychotic intake
n patients treated with at least one FGA (Vita et al., 2015). In con-
rast, less progressive grey matter loss was observed with higher
ean daily antipsychotic intake in patients treated only with SGA
Vita et al., 2015). Whilst subject to the limitations common to all
eta-analyses, these data at least suggest a testable hypothesis for
uture work, but interpretation of the results remains speculative
n the absence of a mechanistic explanation for any such difference
etween FGA and SGA.
A more recent development is the application of existing
nd emerging neuroimaging methods (PET, MRS, Multicomponent
elaxometry [MCR] and Diffusion Tensor Imaging [DTI]) to provide
ndirect evidence for neuroinﬂammation in schizophrenia patients,
y targeting chemical, physical, and geometrical changes that occur
uring the neuroinﬂammatory cascade (Pasternak et al., 2016).
euroinﬂammation represents a complicated cascade of biological
rocesses, which result in subtle biological, chemical, and physical
hanges, all of which may  inﬂuence MR  imaging signals. As a result,
one of the currently available MRI  or PET methods can be said to
e speciﬁc to neuroinﬂammation per se.  The interpretation of these
ndings is therefore limited and very few neuroimaging studies
ave directly investigated the presence of neuroinﬂammation in
chizophrenia patients. Based on the limited available evidence, it
ay  however be stated that if neuroinﬂammation does occur in
chizophrenia, it is likely to be subtle and may  be present in the
arly stages of the disorder (Bloomﬁeld et al., 2016; Filiou et al.,
014; Pasternak et al., 2016, 2015). However, the potential contri-
ution of APD exposure on MRI  and PET methods thought to be
ensitive to inﬂammation remains unknown.
Addressing the potential contribution of APD to brain volume
bnormalities, whether these anatomical changes are progres-
ive with time, and their impact on neuroinﬂammation remains
roblematic in clinical cohorts for the aforementioned reasons.
herefore, pre-clinical studies, in relevant animal models, repre-Please cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
ent a powerful translational approach to address these knowledge
aps. However, animal studies generally focus on a single APD,
ith haloperidol being the prototypical example. More critically,
nd somewhat unfortunately, many animal studies use a dose of PRESS
avioral Reviews xxx (2016) xxx–xxx
antipsychotics that is 10-fold higher than the clinical dose with
inappropriate pharmacokinetics (Harrison, 1999a; Kapur et al.,
2003). An exception to this are the rigorous post-mortem studies
conducted in non-human primates, which used clinic-like plasma
levels and reported that chronic treatment (2.5 years) with either
haloperidol or olanzapine led a ∼10% reduction in total brain weight
and grey/white matter volume as compared to vehicle, particu-
larly in the frontal and parietal lobes (Dorph-Petersen et al., 2005).
Follow-up post-mortem neuropathology studies revealed that the
reductions in parietal lobe grey matter volume in these animals was
due to a decrease in glial cells, with preservation of neuronal num-
bers (Konopaske et al., 2007). Speciﬁcally, chronic APD treatment
led to a ∼20% reduction in S100-immunopositive astrocytes and
a non-signiﬁcant reduction in oligodendroctyes (Konopaske et al.,
2008). Intriguingly, across all three studies there were no signiﬁcant
differences between haloperidol and olanzapine, although the sam-
ple sizes were limited by the species used. However, these single
time-point, cross-sectional, histopathological studies did not use
whole-brain imaging methods, limiting cross-species comparison
with clinical measurements.
To overcome these limitations, we  have implemented a model
in laboratory rats that combines serial in vivo MR imaging (to
delineate the impact & its time course using clinically-comparable
technology), corroborated by high-resolution ex vivo MRI  and post-
mortem histopathology (to identify the cellular basis) and the use of
clinically relevant drug doses and combinations based on matching
D2 receptor occupancy with a method of continuous delivery using
osmotic minipumps (Kapur et al., 2003; Vernon et al., 2011). This
approach has revealed that chronic (8 weeks) treatment with either
haloperidol or olanzapine leads to signiﬁcant reductions in whole-
brain and cortical grey matter volume, conﬁrmed post-mortem
(Vernon et al., 2011) (Fig. 5). For haloperidol at least, these effects
are distinct from those of other psychotropics such as lithium, are
dose-dependent and are apparently reversible on drug withdrawal
(Vernon et al., 2012). Using voxel-wise, operator-independent
tensor-based morphometry (TBM) and cortical thickness measure-
ments, the effects of haloperidol and olanzapine were localised,
in the cortex at least, to the anterior cingulate and somatosen-
sory cortices (Vernon et al., 2014). Post-mortem follow up studies of
the anterior cingulate cortex (ACC) in these animals conﬁrmed no
loss of neurons, but failed to conﬁrm the loss of S100-positive
astrocytes highlighted from the primate studies (Vernon et al.,
2014) (Fig. 6). The reasons behind this discrepancy remain unclear,
but could reﬂect species differences (rats vs. primates), region-
speciﬁc effects (frontal vs. parietal lobe) or differential duration
of exposure, given recent evidence for time-dependent effects on
glial cells in the cortex of antipsychotic exposed rats (Konopaske
et al., 2013). Notably, macaque monkeys treated with APD for 6
months in fact showed increased glial density in the dorsolateral
prefrontal cortex, with no change in cortical thickness (Selemon
et al., 1999), although the doses of APD given to these animals
might not wholly match clinic-like plasma levels (Konopaske et al.,
2007). Extending these ﬁndings, we  recently reported evidence
for profound microglial activation in several regions of the rat
brain following chronic haloperidol or olanzapine treatment (Cotel
et al., 2015), (Fig. 6), which may  have implications for contradictory
ﬁndings regarding putative microglial activation in positron emis-
sion tomography (PET) studies of chronic, medicated schizophrenia
patients (Bloomﬁeld et al., 2015; Doorduin et al., 2009; Kenk et al.,
2015; Takano et al., 2010; van Berckel et al., 2008). It would also
therefore be of interest to examine the effects of chronic antipsy-
chotic exposure on other MRI  and MRS  methods thought to bes to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
sensitive to neuroinﬂammation such as DTI and free-water imaging
(Pasternak et al., 2016, 2015) in this controlled rodent model.
In all these studies, we could not ﬁnd statistically signiﬁcant
differences between the effects of haloperidol and olanzapine,
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n  brain volume, in particular the ability to link macroscale neuroimaging signal ch
lthough a full dose-response study may  be beneﬁcial in this
espect. Further work is also required to fully delineate the cellu-
ar mechanisms underlying these neuroanatomical changes, which
ould reﬂect alterations in synaptic density, axon sprouting, ﬁbre
eorganization, myelin formation, glial cell density, or dendritic
pines or arbours among others. Some support for the latter is evi-
ent again from primate studies in which APD exposure did not
ffect the density of axon terminals (Akil et al., 1999; Glantz and
ewis, 2001) but the density of dendritic spines and the extent of
endritic arborisation were decreased (Lidow et al., 2001). Inter-
stingly, a recent rodent study makes the provocative suggestion
hat changes in dendritic spines at least partially contribute to neu-
oanatomical changes visualised using voxel-based morphometry
nalysis of anatomical MRI  data (Keifer et al., 2015). Studies to unify
hese disparate ﬁndings are now underway in our laboratory, par-
icularly between microglia and dendritic spine alterations given
he provocative suggestion that microglia are critical mediators
f activity-dependent synaptic remodelling and plasticity in the
ealthy brain (Kettenmann et al., 2013).
Although animal studies are inherently useful to dissect the
ffects of antipsychotics on brain structure, provided close atten-
ion is paid to dosing and pharmacokinetics, they are not without
heir limitations. In particular, it is important to stress that the
ajority of these data were collected from naïve animals, which
o not capture the innate pathology of either schizophrenia or
ther psychotic disorders. Furthermore, because the mechanisms
nderlying these effects remain unknown, one should be cautious
n drawing clinical inferences. Nonetheless, our studies provide
 methodological and anatomical framework for future experi-
ents to explicitly examine the relationships between changes in
rain structure and activity, behavior and their post-mortem cellu-
ar correlates after chronic APD treatment, particularly comparing
GA and SGA. Clariﬁcation of these issues will provide importantPlease cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
nsights, which have the potential to aid the clinical management of
chizophrenia and will allow a better understanding of the mecha-
isms underlying the progression of structural brain abnormalities
n schizophrenia and the effects of antipsychotic medication onnology (MRI) reveals new insights into the effects of chronic antipsychotic dosing
 to their microscale cellular correlates.
such progression. Parallel human and animal studies may  be par-
ticularly informative in this respect.
1.3.2. Post-mortem studies of pre-synaptic and glial pathology:
dissecting drug from disease effects
Post-mortem brain tissue is undoubtedly a valuable tool in the
search for the pathophysiology associated with schizophrenia. Fur-
thermore, studies of post-mortem tissue may provide clues to the
cellular and molecular effects of APDs in relevant clinical popu-
lations, negating some of the confounds of animal studies noted
above. Given that schizophrenia subjects included within post-
mortem brain cohorts have typically experienced a chronic disease
course, the majority, if not all, will have been prescribed APD at
some point in their lifetime (Harrison, 1999a,b). As discussed in the
preceding section, it is now evident that antipsychotic medications
can inﬂuence brain morphology with animal models implicating
glial and synaptic/dendritic changes. (Cotel et al., 2015; Konopaske
et al., 2013, 2007, 2008; Lidow et al., 2001; Vernon et al., 2014) In
the following section of this review we  will consider ﬁndings from
post-mortem brain studies in schizophrenia, focussing on presynap-
tic and glial pathology, areas in which we have contributed to the
literature and contemplate how APD exposure may  inﬂuence these
ﬁndings.
Several approaches have been used to assess effects of antipsy-
chotics in post-mortem studies. First, measures may  be compared
between subjects on or off medications around the time of death.
Disadvantages of this approach are that accurate determination
requires access to toxicology measures, furthermore, even if a sub-
ject is not taking medications immediately prior to death, this does
not take into account changes in brain morphology resulting from
medication use over their lifetime (McCullumsmith et al., 2014).
Moreover, depending on the cohort, the number of subjects off
medications prior to death may  be relatively small (Shan et al.,s to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
2013), or large (Barakauskas et al., 2010), thus limiting statisti-
cal power to detect an effect. A second approach is to assess the
correlation between the measure/s of interest and lifetime antipsy-
chotic dose, typically calculated as chlorpromazine or ﬂuphenazine
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quivalents. However, non-adherence to antipsychotic treatment
s commonplace in individuals with schizophrenia (Cramer and
osenheck, 1998). As such, estimates of lifetime antipsychotic dose
re likely to be inaccurate. Furthermore, as discussed already, FGA
nd SGA may  exert differential effects on brain tissue (Ansell et al.,
015; Vita et al., 2015), although this remains to be conﬁrmed in
xperimental models using clinically comparable dosing (Dorph-
etersen et al., 2005; Vernon et al., 2014, 2012, 2011). This factor
s difﬁcult to tease apart in post-mortem studies, given that sam-
le sizes are typically not powered to identify such an effect, and
hat subjects may  have been prescribed both FGA and SGA over
he course of their illness. A ﬁnal, widely used, approach is to
nclude complementary data from pre-clinical studies quantifying
he measure/s of interest in animals, typically rodents or even pri-
ates, treated chronically with antipsychotics as detailed in the
receding section. However, this approach also has its challenges.
he methodology utilized may  not precisely mimic treatment
ourse in humans, for example administration of antipsychotics for
1–28 days, the typical duration of such studies, probably does not
dequately model a lifetime of treatment (McCullumsmith et al.,
014), while it should be remembered that drug half-life is much
horter in rodents (Kapur et al., 2003). Furthermore, investigation
f antipsychotic effects are generally performed in healthy animals
ith no underlying pathology, thus context-dependent differences
r drug x disease interactions have yet to be formally assessed in
etail.
Evidence for pre-synaptic pathology in schizophrenia has
merged from electron microscopy studies (Kolomeets et al., 2005),
lthough research in this area has most commonly involved quan-
iﬁcation of proteins, or their associated transcripts, present in
ynaptic terminals. In particular, proteins associated with vesicle
elease at presynaptic sites, including synaptophysin, the solu-
le N-ethylmaleimide-sensitive factor activating protein receptor
SNARE) proteins SNAP-25, syntaxin, and synaptobrevin (VAMP),
omplexin I and II, synapsin and Rab3a, among others, have been
sed as proxies for synaptic density. Expression of these pre-
ynaptic markers has been explored post-mortem in schizophrenia,
ith decreased abundance reported in several brain regions includ-
ng prefrontal cortex (Glantz and Lewis, 1997; Halim et al., 2003;
oner et al., 1999; Karson et al., 1999; Sawada et al., 2002; Beasley
t al., 2006), hippocampus (Eastwood and Harrison, 1995; Fatemi
t al., 2001; Harrison and Eastwood, 1998; Sawada et al., 2005;
hompson et al., 2003; Vawter et al., 2002; Young et al., 1998),
halamus (Blennow et al., 1996; Davidsson et al., 1999) and ven-
romedial caudate (Barakauskas et al., 2010). However, regional
peciﬁcity may  be implied given changes in presynaptic protein
bundance were not reported in visual cortex (Glantz and Lewis,
997; Thompson et al., 1998), visual association cortex (Beasley
t al., 2005), orbitofrontal cortex (Ramos-Miguel et al., 2015),
r nucleus accumbens (Barakauskas et al., 2010). Furthermore,
ecreased (Landen et al., 2002), unchanged (Barksdale et al., 2014;
astwood and Harrison, 2001; Ramos-Miguel et al., 2015) and
ncreased (Gabriel et al., 1997; Honer et al., 1997) levels of pre-
ynaptic proteins have been noted in the anterior cingulate region.
ata from studies quantifying transcript expression are more dif-
cult to interpret. While results from targeted investigations of
re-synaptic markers have found no consistent group differences
Fung et al., 2011; Glantz et al., 2000; Karson et al., 1999), sev-
ral genome-wide microarray studies have identiﬁed enrichment
f transcripts associated with synaptic function, including vesicle
ynamics (Arion et al., 2007; Maycox et al., 2009; Mirnics et al.,
001; Mudge et al., 2008; Schmitt et al., 2012). Measures of pre-Please cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
ynaptic proteins are typically interpreted as reﬂecting synaptic
ensity. However, alterations in synaptic size, vesicle number or
esicle release cannot be ruled out. Enhanced SNARE complex for-
ation has been reported in several brain regions in schizophrenia PRESS
avioral Reviews xxx (2016) xxx–xxx
(Barakauskas et al., 2010; Honer et al., 2002; Ramos-Miguel et al.,
2015) and may  be suggestive of altered vesicle dynamics and synap-
tic dysfunction.
We suggest that the deﬁcits in pre-synaptic markers detailed
above are unlikely to be a consequence of antipsychotic use, based
on multiple lines of evidence. Several studies have failed to identify
signiﬁcant correlations between lifetime antipsychotic dose and
abundance of pre-synaptic proteins (Beasley et al., 2005; Gray et al.,
2010; Halim et al., 2003), while comparisons between schizophre-
nia subjects prescribed APD immediately prior to death and those
who were not indicate no difference in synaptic protein levels
(Gabriel et al., 1997; Honer et al., 1997). Findings from pre-clinical
studies examining pre-synaptic protein abundance in rodents are
more mixed, although it should be noted that the majority of
these studies have not used clinically comparable dosing (Kapur
et al., 2003). Nevertheless, studies have either reported no effect of
antipsychotics (Ramos-Miguel et al., 2015; Sawada et al., 2005),
or increases in pre-synaptic protein levels in the hippocampus
and cortex following APD administration (Barr et al., 2006; Scarr
and Dean, 2012). Intriguingly, pre-synaptic protein and transcript
expression is greater in the striatum following haloperidol admin-
istration (Barakauskas et al., 2010; Eastwood et al., 1994; Marin and
Tolosa, 1997), consistent with the striatal hypertrophy induced by
clinically comparable chronic haloperidol treatment in rats (Vernon
et al., 2012) and with clinical MRI  studies indicating increased stri-
atal or pallidal volume in subjects with schizophrenia (van Erp et al.,
2015). Overall, the evidence suggests that the predominant deﬁcits
in pre-synaptic proteins found in post-mortem studies are likely
associated with the disease process rather than antipsychotic use,
at least in cortical regions. This is further supported by recent ﬁnd-
ings from GWAS datasets, which heavily implicate synaptic genes
and pathways in schizophrenia neurobiology (Anon, 2015; Fromer
et al., 2014). However, a role for increased synaptic density, and/or
changes in synaptic morphology, in antipsychotic-associated stri-
atal hypertrophy is plausible(Konradi and Heckers, 2001)
The glial complement of the CNS is comprised of three major cell
populations; oligodendrocytes, astrocytes and microglia. Oligoden-
drocytes are the major myelinating cells (Baumann and Pham-Dinh,
2001), astrocytes have been implicated in many essential CNS
processes, including neurotransmission, glucose metabolism and
regulation of blood ﬂow, in addition to neuroprotection and
response to injury (Sofroniew and Vinters, 2010), while microglia
play an essential role in the brain’s response to damage and may
also act as a mediator of CNS synaptic plasticity (Tremblay, 2011).
Dysfunction of all three glial populations has been implicated in the
pathophysiology of schizophrenia (Trepanier et al., 2016).
Decreased oligodendrocyte density has been reported in pre-
frontal grey matter in schizophrenia (Hof et al., 2003; Uranova et al.,
2004; Vostrikov et al., 2007), however, in white matter, where the
majority of oligodendrocytes are located, evidence for decreased
oligodendrocyte density (Hof et al., 2003; Kerns et al., 2010) is out-
weighed by studies ﬁnding no signiﬁcant change (Hercher et al.,
2014; Mosebach et al., 2013; Segal et al., 2009; Uranova et al., 2004;
Williams et al., 2013b). Quantiﬁcation of myelin-associated pro-
teins and associated transcripts has also produced mixed results.
While global transcriptomic (Hakak et al., 2001; Katsel et al., 2005;
Tkachev et al., 2003) and proteomic (Pennington et al., 2008) stud-
ies have identiﬁed changes in grey matter, and to a lesser degree
white matter, in schizophrenia, the ﬁndings are not consistent with
several targeted investigations of myelin protein or mRNA expres-
sion (Barley et al., 2009; Beasley et al., 2009, 2005; Hercher et al.,
2014; McCullumsmith et al., 2007; Mitkus et al., 2008).s to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
The effects of antipsychotics on oligodendrocytes and myelin are
presently unclear. Bartzokis and colleagues proposed that antipsy-
chotics, in particular SGAs, have a protective or myelin promoting
effect (Bartzokis et al., 2009), however, post-mortem studies have
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ailed to provide evidence consistent with this theory. Comparisons
f schizophrenia subjects on or off medication revealed no group
ifferences in myelin transcripts (McCullumsmith et al., 2007),
hile several studies have reported a lack of signiﬁcant correla-
ion between antipsychotic dose and abundance of myelin proteins
Beasley et al., 2005; Hercher et al., 2014) or transcripts (Kerns et al.,
010; Mitkus et al., 2008). Conversely, we observed a negative cor-
elation between lifetime antipsychotic dose and oligodendrocyte
ensity in prefrontal white matter (Hercher et al., 2014). This is
onsistent with a study of the parietal cortex of rhesus monkeys
ollowing chronic antipsychotic exposure, which reported numeri-
ally reduced numbers of oligodendrocytes, although this failed to
each statistical signiﬁcance (Konopaske et al., 2008). Corpus cal-
osum volume, visualized on MR  images, was also not signiﬁcantly
ffected by chronic haloperidol or olanzapine treatment in rodents
Vernon et al., 2011), although, this does not preclude a decrease in
ligodendrocytes, balanced by an increase in another cell type such
s microglia, which may  be altered in the white matter following
reatment with the same drugs (Cotel et al., 2015). Further explo-
ation of the effects of APD on white matter, oligodendrocytes and
yelination are therefore warranted.
Contemporary post-mortem studies of astrocyte density in
chizophrenia have typically utilized the marker glial ﬁbrillary
cidic protein (GFAP). Results to date have been somewhat incon-
istent; lower density of GFAP-positive astrocytes have been
eported in cortex in some studies (Rajkowska et al., 2002; Williams
t al., 2013a), whilst others have failed to identify signiﬁcant group
ifferences (Arnold et al., 1996; Damadzic et al., 2001; Falkai et al.,
999; Radewicz et al., 2000). Of note, GFAP is expressed at relatively
ow levels in the protoplasmic astrocytes located in cerebral cortex,
nd is considered a more reliable marker of the ﬁbrous astro-
ytes present in white matter (Middeldorp and Hol, 2011). While
ecreased astrocyte density has also been reported in white matter
n schizophrenia (Williams et al., 2013a), this result is discrepant
ith two further studies that found no signiﬁcant differences
etween groups (Falkai et al., 1999; Hercher et al., 2014), although
t is worth mentioning that the latter study noted lower GFAP
rea fraction in schizophrenia, suggestive of altered astrocyte cell
orphology or function. Overall, data from studies quantifying the
ensity of GFAP-positive astrocytes are inconsistent with the pres-
nce of gliosis in this disorder. Having said that, cellular ﬁndings,
longside reports of regionally speciﬁc decreases (Johnston-Wilson
t al., 2000; Katsel et al., 2011; Steffek et al., 2008; Toro et al., 2006;
ebster et al., 2005), or increases (Barley et al., 2009; Feresten et al.,
013; Pennington et al., 2008; Rao et al., 2013; Toro et al., 2006) in
FAP or other astrocyte-associated protein or mRNA expression are
otentially consistent with altered astrocyte function.
The impact of antipsychotics on astrocyte density or function
emains to be elucidated, although current evidence suggests that
xposure to APD may  up-regulate astrocyte density or GFAP pro-
uction. Positive relationships between GFAP levels and lifetime
ntipsychotic dose have been observed post-mortem (Barley et al.,
009; Toro et al., 2006), although others have reported no signiﬁ-
ant correlation between dose and GFAP-positive astrocyte density
Hercher et al., 2014) or protein abundance (Feresten et al., 2013;
ennington et al., 2008), or no effect of medication history on
strocyte-associated protein levels (Rao et al., 2013). Complemen-
ary pre-clinical studies in animals administered antipsychotics
o not fully resolve this issue, Chronic APD treatment resulted
n a reduction in S100-immunopositive astrocytes in macaques
Konopaske et al., 2008), however increased GFAP-positive astro-
yte density was reported in rhesus monkeys administered FGAPlease cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
r SGA antipsychotics for six months (Selemon et al., 1999),
hilst greater S100-positive astrocyte density was observed in
he frontal cortex of rats (Vernon et al., 2014) following chronic
ntipsychotic treatment. In general, GFAP abundance appears to PRESS
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be unchanged following haloperidol exposure in rats (Dean et al.,
2006; Fatemi et al., 2008; Feresten et al., 2013; Steffek et al., 2008),
although we found trends towards increased GFAP and aldehyde
dehydrogenase L1 levels (Feresten et al., 2013). Clearly, further
work using multiple astrocyte markers and different antipsychotics
is required to clarify these effects.
Despite substantial recent interest in the role of inﬂammation
in schizophrenia, conclusive evidence for the presence of inﬂam-
matory changes in the CNS remains elusive. Cellular investigations
of microglial density have produced inconsistent results; while
increased density of HLA-DR-positive microglia was reported in an
early study (Radewicz et al., 2000), subsequent attempts to repli-
cate this ﬁnding have revealed either no change (Hercher et al.,
2014; Steiner et al., 2006), or subtle increases restricted to subpopu-
lations of subjects (Fillman et al., 2013; Steiner et al., 2008). Reports
of increased abundance of the microglial marker CD11b, or mea-
sures of putative microglial activation, such as pro-inﬂammatory
cytokines or nuclear factor kappa B, in schizophrenia (Fillman et al.,
2013; Paterson et al., 2006; Rao et al., 2013; Volk et al., 2015)
provide some evidence for an inﬂammatory response, although
divergent ﬁndings also exist (Dean et al., 2013; Fillman et al., 2014;
Roussos et al., 2013).
While there is some evidence that antipsychotics may  pos-
sess anti-inﬂammatory properties, these claims are often based
on in vitro, non-clinical doses in vivo, or single doses of antipsy-
chotics (Kato et al., 2011; Shin and Song, 2014; Venneti et al.,
2006; Zhu et al., 2014). Indeed, post-mortem studies currently pro-
vide little credible evidence for either pro-or anti-inﬂammatory
action of APD, noting no signiﬁcant relationship between life-
time antipsychotic dose and density of activated or total microglia
(Hercher et al., 2014; Radewicz et al., 2000; Steiner et al., 2008),
and no association between medication history and expression
of molecules associated with microglial activation (Rao et al.,
2013; Volk et al., 2015). Furthermore, mRNA expression of pro-
inﬂammatory cytokines is not altered in monkeys chronically
exposed to haloperidol or olanzapine, although this study utilised
whole tissue homogenates rather than microglial fractions (Volk
et al., 2015). In contrast, recent evidence suggests that chronic
treatment with both FGA and SGA may  precipitate a shift towards
reactive, amoeboid microglial morphology in rat brain (Cotel et al.,
2015). However the consequences of this microglial activation and
the functional state of these cells along the simplistic but widely
used M1  (pro-inﬂammatory) and M2  (anti-inﬂammatory) polar-
isation remains to be clariﬁed (Cotel et al., 2015). In addition,
the relationship between antipsychotic exposure and expression
levels of the translocator protein (TSPO) remain unclear. This is
relevant since radio-ligands targeting TSPO are used as a clinical
imaging index of putative microgliosis (Pasternak et al., 2016). Fur-
ther studies are therefore warranted to dissect the relationships
between chronic antipsychotic treatment and the immune sys-
tem (Cotel et al., 2015). Overall, while post-mortem studies provide
some evidence for lower oligodendrocytes and astrocyte density
and increased microglial density, ﬁndings are equivocal. The role of
APDs in glial pathology in schizophrenia remains subject to debate.
1.4. Metabolic side effects of antipsychotic drugs: the role of
insulin signalling
Over the past 2 decades, the introduction of SGA has shed light
on serious metabolic side-effects related to these agents, includ-
ing weight gain, dyslipidemias, and glucose dysregulation diabetes
(Allison et al., 1999a; Mackin, 2005; Nasrallah and Newcomer,s to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
2004; Wirshing et al., 1998). The importance of gaining a bet-
ter understanding of how these agents may  be contributing to
the metabolic burden that characterizes those with serious men-
tal illness is highlighted by the observation that the leading
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ause of death in this population is attributable to cardiovascular
isease (CVD) (Hennekens et al., 2005). While there exists a dif-
erential metabolic liability between the various individual agents
with clozapine and olanzapine conferring the greatest metabolic
isk)(Allison et al., 1999b; Lieberman et al., 2005a), it has become
lear that no single agent is devoid of this risk. This observation is
ighlighted in ﬁrst episode schizophrenia patients with little prior
xposure to these medications (e.g. antipsychotic naïve) that have
onsistently been shown to be at increased risk for antipsychotic-
nduced metabolic adverse events (Correll et al., 2009; Patel et al.,
009; Perez-Iglesias et al., 2007; Zipursky et al., 2005). The impli-
ations of these observations are concerning and extend beyond
ardiovascular health risks; in psychiatric populations medical
omorbidity (including weight gain and diabetes) has been found
o adversely affect medication compliance, self-esteem, quality of
ife, and functional outcomes (Adriano et al., 2012; De Hert et al.,
006a; Gold et al., 2007; Lyketsos et al., 2002). Moreover, obe-
ity and glucose dysregulation have been linked to structural brain
hanges that may  overlap with, and exacerbate, those characteriz-
ng schizophrenia (Adriano et al., 2012; Gold et al., 2007), although
xperimental evidence from rodent models is lacking.
Weight gain is a well-established risk factor for other cardio-
ascular morbidities including dyslipidemias, metabolic syndrome,
nd type 2 diabetes. In particular, as compared to the general
opulation, patients with schizophrenia have a 3–5 fold increased
revalence rate of type 2 diabetes (De Hert et al., 2006b). However,
he underlying etiology of this serious cardiovascular morbidity is
ot a straightforward phenomenon. Contributing effects include
ntipsychotic-induced weight gain (adiposity is a leading risk fac-
or for type 2 diabetes), illness-related lifestyle factors (inactivity,
igh smoking rates, poor dietary habits), and a possible genetic pre-
isposition to type 2 diabetes (Brown et al., 1999; Kohen, 2004;
ukherjee et al., 1989). Further adding to underlying complexity,
PD have been shown to acutely, and directly impact molecular
athways of lipid and glucose metabolism.
It is now well accepted that APD can “directly” impair insulin
ensitivity independently, and in addition to their weight gain
ropensities. Early evidence of this “direct” antipsychotic-induced
henomenon was supported by case reports of diabetic ketoaci-
osis in association with APD occurring even in the absence
f weight gain (Guenette et al., 2013). Subsequent studies in
atients on APD demonstrated that risk of glucose dysregulation
ould occur independently of indices of body weight (Henderson
t al., 2005; Newcomer et al., 2002). However, to directly exam-
ne effects of these drugs on glucose metabolism avoiding any
onfounding effects of illness and weight gain, researchers also
urned to the use of healthy/non-obese rodents, treated with
cute doses of APD (avoiding early changes in adiposity). Indeed,
ork in rodents administered acute doses of an antipsychotic
onsistently demonstrate impairments in insulin sensitivity (hep-
tic and peripheral), and glucose tolerance (Albaugh et al., 2011,
012; Boyda et al., 2010; Chintoh et al., 2009, 2008; Houseknecht
t al., 2007; Martins et al., 2010). These perturbations appear to
enerally follow the metabolic liability observed in clinic (olan-
apine, clozapine > risperidone > haloperidol), with early evidence
lso suggesting that newer SGA, considered to be more metaboli-
ally neutral (e.g. lurasidone) are also characterized by a degree of
erangement in glucose homeostasis (Wu et al., 2013).
Emerging evidence also suggests that the direct effects of APD on
lucose homeostasis can be modeled in humans. Analogous to what
s seen in rodents, studies in healthy, normal weight volunteers,
xamining sub-acute (8–10 days) or acute (1–3 days) APD adminis-Please cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
ration have shown early changes in glucose metabolism (Albaugh
t al., 2011; Hahn et al., 2013a, 2013b; Sacher et al., 2008; Teff et al.,
013; Vidarsdottir et al., 2010a, 2010b). Interestingly, among those
tudies, Teff et al. suggested that even aripiprazole, an agent con- PRESS
avioral Reviews xxx (2016) xxx–xxx
sidered to be metabolically neutral, could induce early changes in
insulin sensitivity (Teff et al., 2013). Thus, within the consideration
that humans have greater physiological complexity and genetic
heterogeneity than bred rodent strains, evidence suggests trans-
lational validity between these species in APD-associated glucose
dysmetabolism. This observation in turn implies that rodent mod-
els of antipsychotic-induced glucose dysregulation may be useful to
elucidate underlying mechanisms of these disturbances, including
use of invasive techniques/tissue harvesting which are not feasible
in humans.
The concept of brain-mediated regulation of glucose homeo-
stasis emerged as early as the 1850′s, with the demonstration that
puncture of the 4th ventricle in rabbit’s results in glycosuria. Today,
it is well-established that peripheral hormones and nutrient signals
communicate with the brain through respective central nervous
system (CNS) receptors, resulting in preservation of energy and glu-
cose homeostasis (Sandoval et al., 2008). The question thus emerges
whether APD, which exert therapeutic mechanisms through the
CNS, may also be causing metabolic perturbations through overlap-
ping mechanisms. Indeed, many of the neurotransmitters and their
respective receptors that are implicated in energy/glucose homeo-
stasis, are impacted by APD (Nasrallah, 2008). As a starting point
to disentangling potentially complex CNS-mediated mechanisms of
antipsychotic-induced glucose dysregulation, it is ﬁrst important to
establish that APD impair glucose homeostasis through the brain.
By employing stereotaxic techniques, it is possible to administer
APD directly into speciﬁc brain regions and (precluding leakage
into periphery) attribute any perturbations in glucose metabolism
to CNS-mediated pathways. To our knowledge, three such studies
exist (Girault et al., 2012; Hahn et al., 2014; Martins et al., 2010).
Martins et al. administered a primed continuous infusion of olan-
zapine (330 g total) during a hyperinsulinemic euglycemic clamp
(HIEC), considered the gold standard to measure insulin sensitivity.
They noted increased hepatic glucose production during hyperin-
sulinemia, suggesting that centrally mediated mechanisms may
explain olanzapine-induced hepatic insulin resistance (Martins
et al., 2010). Our own group examined a central bolus of olanzapine
(75 g total) during separate hyperglycemic clamps (to examine
insulin secretion), and hyperinsulinemic euglycemic clamps (HIEC)
(to examine peripheral and hepatic insulin sensitivity). Interest-
ingly, in contrast to our work examining systemic, or peripheral
olanzapine administration, intracerebroventricular (ICV) olanzap-
ine administration failed to induce peripheral or hepatic insulin
resistance, but replicated an impaired insulin response to glucose
challenge. These data suggest that olanzapine-induced decrements
in ß-cell function could be mediated in part through CNS mecha-
nisms (Hahn et al., 2014). A recent study similarly examined central
administration of olanzapine during an HIEC (total dose 36 g), fail-
ing to ﬁnd effects on any parameters on insulin sensitivity (Girault
et al., 2012; Martins et al., 2010). The reason behind observed dis-
crepancies between studies is unknown, but might be explained by
differences in dosing. Our work employed a quantitative method
to establish ICV olanzapine dosing (i.e. inhibition of amphetamine-
induced locomotion) (Hahn et al., 2014) where as the other groups
used qualitative dose determination (observed sedative effects)
(Girault et al., 2012). That said, as outlined in the preceding sec-
tions, D2 receptor brain occupancies remain the gold standard by
which to establish therapeutic dose, and to our knowledge this has
not yet been determined for ICV APD administration.
Addressing the limitations of currently available work to
develop a model capable of dissecting contributing central effects
of APD on glucose metabolism may  have implications extend-s to antipsychotic drugs: Insights from pre-clinical and human
g/10.1016/j.neubiorev.2016.10.004
ing beyond understanding the underlying metabolic burden. As
reviewed by others, the D2 receptor (central to our understanding
of antipsychotic action) has been linked to CNS insulin signaling
(Caravaggio et al., 2015; Girgis et al., 2008). Mounting evidence
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uggests that insulin action in the brain exerts important regula-
ory functions on energy and glucose homeostasis (Filippi et al.,
012). Taken together, the possibility exists that APD therapeu-
ic efﬁcacy and metabolic side effects represent an overlapping
henomenon, possibly via CNS insulin signaling. Within the con-
eptualization of D2 antagonism as the common denominator for
PD therapeutic efﬁcacy, this hypothesized link fails to explain
hy antipsychotics with the greatest metabolic liability appear
o have superior therapeutic efﬁcacy (i.e. clozapine, and possibly
lanzapine). However, the possibility exists that combinations of
eceptor synergisms or other poorly elucidated pathways (e.g. neu-
oinﬂammation) converge on pathways of therapeutic efﬁcacy and
etabolic deregulation. If this is true, future work in this area will
e important to determine if it is possible to maximize therapeu-
ic efﬁcacy while targeting, or avoiding metabolic perturbations.
urthermore, early evidence might suggest that the answer to
his question may  be dependent on the speciﬁc domain of psy-
hopathology under consideration. For example, in patients with
chizophrenia, impaired glucose tolerance and decreased insulin
ensitivity have been linked to decreased positive symptoms (Chen
t al., 2013; Kirkpatrick et al., 2009) (Kirkpatrick et al., 2009;
hang et al., 2015). Conversely, obesity and glucose dysregula-
ion have been linked to cognitive deﬁcits and brain volume loss
Adriano et al., 2012; Gold et al., 2007; van den Berg et al., 2009).
aken together, it is tempting to speculate that further investi-
ation of mechanisms underlying antipsychotic-related metabolic
ide-effects, in particular glucose dysmetabolism, may  be crucial to
eveloping understanding of psychopathology, and interventions
eyond current widely accepted models. Arguably, rodent models
f antipsychotic-induced glucose dysregulation may  hold a unique
lace in moving this ﬁeld forward given their empirical practicality,
nd translational value to the clinic. Combination with neuroimag-
ng to examine relationships between body fat (Mondelli et al.,
013), and brain structural and functional changes (Vernon et al.,
011) in relation to peripheral metabolic dysfunction may  be of
articular interest.
. Conclusions
In this review, we integrate clinical and pre-clinical evidence
rom studies of antipsychotic efﬁcacy, effects on neuroimaging
ignatures, metabolic side effects and post-mortem human brain
issue. A parsimonious synthesis of these parallel lines of research
ould suggest the following conclusions. First, in terms of antipsy-
hotic efﬁcacy, the serotonin output pattern of APD may  offer an
mproved means of classiﬁcation, compared to the 5-HT2A/D2 ratio
or deﬁning the mechanism of action of antipsychotics, particu-
arly for newer SGA compounds and their likely clinical efﬁcacy.
elated to this, we present the ﬁrst suggestion that clinical out-
omes should be examined based on their relationship with the
erotonin and other neurotransmitter output driven by different
PD. This efﬁcacy biomarker as deﬁned here may  be valuable to
nvestigate the mechanisms of treatment failure. Second, there is
ow compelling evidence from both clinical and pre-clinical MRI
tudies that strongly suggests the dose and duration of APD treat-
ent is associated with alterations in brain volume. Nevertheless,
mportant questions remain unanswered. In particular the mech-
nism driving this effect and whether there are differential effects
f FGA and SGA remain unknown and unqualiﬁed. More impor-
antly, accepting that these changes do occur, the ultimate clinical
onsequences of antipsychotic-induced changes in brain volumePlease cite this article in press as: Amato, D., et al., Neuroadaptation
post-mortem studies. Neurosci. Biobehav. Rev. (2016), http://dx.doi.or
emain unclear. While post-mortem brain studies in schizophre-
ia implicate alterations in synapses and glial cells, the potential
mpact, if any, of APDs on these ﬁndings remains to be determined,
lthough evidence suggest that some features, particularly cortical PRESS
vioral Reviews xxx (2016) xxx–xxx 13
pre-synaptic changes, appear to be organic to the disease process.
Finally, it has been long accepted that antipsychotics induce detri-
mental metabolic alterations, particularly SGA. Yet surprisingly
little is still known about the mechanisms underlying these effects,
how to obviate them and how they impact on brain structural and
behavioral observations in patients.
A common vein running through these sections is the criti-
cal importance of utilizing animal models to dissect the precise
effects of antipsychotics, on both the cellular and molecular level
but also at a gross scale to link these to alterations in brain struc-
ture, function and behaviour. Provided close attention is paid to
the use of clinically relevant dosing and effective use of clini-
cally comparable technology (e.g. neuroimaging) such models have
the potential to yield important insights, for example, the inter-
relationships between metabolic abnormalities and brain function
in addition to clarifying ﬁndings from post-mortem studies. An
important omission, however, is that often these studies are done
in naïve animals, in the absence of neuropathological changes rele-
vant to schizophrenia. Whilst studies in naïve animals are crucial to
begin to unravel APD effects, it is clear that the ﬁeld now needs to
move beyond this and begin systematic assessment of APD effects
in relevant pathological model systems. Whilst this is a mineﬁeld
in itself, as no animal model can recapitulate all features of this
uniquely human disease, it may  be possible using a reductionist
approach to assess the impacts of antipsychotics on certain fea-
tures. For example, chromosome 22q11.2 deletion syndrome is a
neurogenetic disorder associated with high rates of schizophrenia
and other psychiatric conditions (Schneider et al., 2014). A mouse
model of the 22q11.2 deletion (Df(16)A(+/−)) shows remarkable
anatomical overlap with human patients including alterations
in cortico-cerebellar, cortico-striatal and cortico-limbic circuits
(Ellegood et al., 2014). Such model therefore could provide a basis
to test the effects of APD on brain volume alterations in a disease-
speciﬁc context, although, many other such approaches may  be
visualized. Ultimately, we  propose that gaining a deeper under-
standing of the effects of long-term APD treatment on the brain and
body at the cellular and molecular level, may ultimately inform the
clinical use of these drugs and, moreover, the development of new
antipsychotic agents.
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